Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a biological product manufacturing company that describes its mission as building the tools that make biology easier to engineer. The DNA stock news page on Stock Titan aggregates company announcements, collaborations, and regulatory updates so investors and observers can follow how Ginkgo’s platform is being applied across sectors.
According to Ginkgo’s public statements, its business spans cell engineering services, biosecurity offerings, modular lab automation, large-scale biological data generation, and agricultural biologicals R&D. News about Ginkgo Bioworks often covers new partnerships with academic institutions, biotechnology companies, and government agencies, as well as updates on projects funded by U.S. health and research organizations. These stories illustrate how the company’s R&D Solutions, Automation, Datapoints, Agriculture, and Biosecurity units are used in real-world programs.
Typical Ginkgo Bioworks news items include announcements of research collaborations in areas like cancer screening, drug safety modeling, and in vivo cell and gene therapy; contracts for high-throughput phenotyping platforms and biosecurity-related capabilities; and agreements to optimize fermentation and bioprocesses for agricultural soil amendments and biological crop solutions. Investors can also find information about extended strategic partnerships in agriculture and other markets.
This page may also surface press releases tied to quarterly financial results, conference presentations, and other investor communications referenced in the company’s filings. By reviewing the DNA news feed, users can see how Ginkgo Bioworks positions its platform, how its collaborations evolve over time, and how its activities relate to the broader biological product manufacturing and synthetic biology landscape.
Ginkgo Bioworks (NYSE: DNA) has integrated the Callisto™ Sample Prep System into their routine Illumina sequencing workflow. The system, developed by Volta Labs, addresses the automation challenges in DNA clean-up processes, particularly for high-throughput labs handling thousands of samples.
The Callisto system features an App Store concept that enables access to multiple sequencing technologies and chemistries on a single platform, helping maintain low operating costs. A notable addition is the Size Selection app, which allows short-read labs using Illumina, Element Biosciences, and Ultima Genomics platforms to purify and select optimal fragment sizes for sequencing.
The system's advanced electrowetting, magnetic, and acoustic capabilities, along with its proprietary VoltaNode™ technology, enable precise liquid separation, efficient DNA elution from beads, and flexible batch processing.
Ginkgo Bioworks (NYSE: DNA) has announced a partnership with the European Health and Digital Executive Agency (HaDEA) in a consortium project worth up to €24 million over 4 years. The project, named RANGER (RApid Next Generation Sequencing for Effective Medical Response), aims to develop a rapid point-of-care diagnostic solution for respiratory viruses.
The initiative will create a device capable of identifying virtually any respiratory pathogen through metagenomic next-generation sequencing (mNGS) with a 6-hour turnaround time. The program includes an option for the European Commission to procure 200 devices at preferred pricing.
The project will be executed in three phases, involving technology development with partners Jumpcode, TGen, Bugseq, and Planet Innovation, followed by clinical trials in EU hospitals, and finally EU certification. The consortium includes partnerships with KU Leuven, Karolinska University Hospital, and Tartu University Hospital for clinical trials.
Ginkgo Bioworks (NYSE: DNA) has scheduled its Q4 and full year 2024 financial results presentation for Tuesday, February 25, 2025, at 5:30 p.m. ET. The presentation will include a business performance review and Q&A session.
Investors can access the presentation and webcast through Ginkgo's investor relations website, with a replay option available afterward. Questions can be submitted in advance via X (using #GinkgoResults) or email to investors@ginkgobioworks.com.
Ginkgo Bioworks (NYSE: DNA) has announced its 2025 Ferment Series, transforming its annual conference into multiple focused events throughout the year at their Boston Seaport District venue. The series will showcase Ginkgo's cell engineering and biosecurity offerings, featuring presentations from company experts, partners, and industry leaders.
The events will highlight new products and services, including Ginkgo Datapoints' AI-driven data generation services, Ginkgo Automation's Reconfigurable Automation Cart systems, and Ginkgo Biosecurity's product suite featuring Canopy and Horizon platforms.
The series includes four main events: Summer's Datapoints x AI focus on biotech R&D, September's Biopharma Solutions showcase, October's Biosecurity discussions, and November's Automation demonstrations. Additionally, Ginkgo will participate in World AgriTech in San Francisco (March) and ABIM (October), including a tour of their West Sacramento R&D facility. A larger, platform-wide Ferment will return in 2026.
Ginkgo Bioworks (NYSE: DNA) announced that its Ginkgo Automation division will design and deploy a flexible laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC) at the University of Wisconsin–Madison. The system aims to support biofuels and bioproducts research from plant biomass.
The new anaerobic-capable automation system will enable GLBRC scientists to run multiple experiments simultaneously across both aerotolerant and anaerobic conditions, increasing efficiency and 'walkaway' time. The system includes access to Catalyst Flow, a remote error resolution service expected to resolve 80-90% of system errors without user intervention.
Built on expertise from Ginkgo Bioworks and Zymergen, the customizable system focuses on automating workflows for anaerobic organisms, a key requirement for GLBRC's research programs. The technology aims to help GLBRC advance its mission of enabling cost-effective, sustainable biofuel production at scale.
Ginkgo Bioworks (NYSE: DNA) has announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. The partnership aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics for solid tumors.
The collaboration combines Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in design and screening large CAR libraries and its high-throughput, multimodal immune cell engineering platform. Ginkgo's approach utilizes computational tools, library assembly and screening expertise, and statistical analysis to accelerate therapeutic design optimization.
The platform enables simultaneous testing of numerous CAR designs from transcriptome to cell function, focusing on improving immune cell persistence and functionality. This partnership represents a significant expansion of Ginkgo's cell therapy portfolio.
Ginkgo Bioworks (NYSE: DNA), a company focused on cell programming and biosecurity, announced that its Co-Founder and CEO Jason Kelly will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 16, 2025, at 10:30 a.m. PT (1:30 p.m. ET). A webcast link and replay will be available on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has been awarded a $9.4 million subcontract in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices for treating hormone disorders under ARPA-H's REACT program. The BIO-INSYNC project focuses on creating implantable devices that can produce therapeutic molecules and monitor disease biomarkers in real-time for at least one year after implantation.
The initiative will initially target thyroid disorders, developing systems to measure thyroid hormone levels and produce required doses. Patients and healthcare providers will be able to monitor and control the treatment via smartphone. The project combines Ginkgo's expertise in mammalian cell and iPSC engineering with Carnegie Mellon's bioelectronics capabilities, along with researchers from the University of Pittsburgh, University of Florida, and UC Santa Cruz.
Ginkgo Bioworks (NYSE: DNA) reported Q3 2024 financial results with total revenue of $89 million, up 61% year-over-year, including a $45 million non-cash revenue from deferred revenue release. Excluding this impact, revenue was $44 million, down 21%. Cell Engineering revenue decreased 20% to $30 million, while Biosecurity revenue fell to $14 million. The company reported a Loss from operations of $(55) million and Adjusted EBITDA of $(20) million. Ginkgo updated its 2024 guidance to $215-235 million in total revenue. The company achieved cost reductions through restructuring, estimating over $85 million in annualized savings by mid-2025.
Ginkgo Bioworks (NYSE: DNA) has successfully completed the first milestone in its partnership with Merck focused on improving biologic manufacturing. The achievement triggers a $9 million cash research milestone payment to Ginkgo. The collaboration will now proceed to its second stage, continuing efforts to enhance production processes. Ginkgo will leverage its strain engineering, high-throughput screening, and process development capabilities to support this pharmaceutical partnership.